P. Julier

发表

VICTOR: A PHASE III PLACEBO-CONTROLLED TRIAL OF ROFECOXIB IN COLORECTAL CANCER PATIENTS FOLLOWING SURGICAL RESECTION

D. Kerr, C. McConkey, J. Dunn, 2008 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off

J. Nguyen-Van-Tam, D. Altmann, V. Barber, 2022, BMJ Open.

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

H. Williams, J. A. Cook, S. Hider, 2022, The Lancet Respiratory Medicine.

LBA12FINAL RESULTS FROM QUASAR2, A MULTICENTRE, INTERNATIONAL RANDOMISED PHASE III TRIAL OF CAPECITABINE (CAP) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT SETTING OF STAGE II/III COLORECTAL CANCER (CRC)

D. Kerr, I. Tomlinson, S. Love, 2014 .

A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

A. Pagnamenta, D. Kerr, A. González-Neira, 2014, Gut.

Phase III Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial of Gefitinib versus Placebo in Esophageal Cancer Progressing after Chemotherapy, COG (Cancer Oesophagus Gefitinib)

D. Ferry, S. Dutton, R. Hubner, 2012 .

Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study

M. Gulati, Jennifer A. Williams, S. Dutton, 2022, The Lancet. Rheumatology.

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

D. Ferry, S. Dutton, J. Blazeby, 2014, The Lancet. Oncology.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial.

D. Kerr, I. Tomlinson, S. Love, 2016, The Lancet. Oncology.

Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.

D. Kerr, C. McConkey, J. Dunn, 2007, The New England journal of medicine.

Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.

D. Kerr, C. McConkey, B. Warren, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.

D. Kerr, J. Pignon, A. González-Neira, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.

D. Ferry, S. Dutton, J. Blazeby, 2014, The Lancet. Oncology.

Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project

P. Julier, Joanna Black, Lucy Eldridge, 2024, Trials.

Phase II clinical trial of six mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumors.

S. Kaye, A. Schuh, M. Hall, 2013 .

Breast cancer, early stage

M. Espié, C. Mermel, R. Gelber, 2012 .